Kawasaki disease: epidemiology and the lessons from it

Y Nakamura - International Journal of Rheumatic Diseases, 2018 - Wiley Online Library
A half of century has passed since Dr. Tomisaku Kawasaki reported his 50 cases with
Kawasaki disease (KD) in 1967. Since then, more than 300 000 cases have been reported …

The therapeutic window of intravenous immunoglobulin (IVIG) and its correlation with clinical outcomes in Kawasaki disease: a systematic review and meta-analysis

Z Li, J Cai, J Lu, M Wang, C Yang, Z Zeng… - Italian Journal of …, 2023 - Springer
Background The optimal therapeutic window to start intravenous immunoglobulin (IVIG) for
Kawasaki disease (KD) is highly debatable. We aimed to summarize the existing literature to …

Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy

J Liu, B Ye, D Su, S Qin, W Zhao, Y Pang - Clinical Rheumatology, 2023 - Springer
Objectives We aimed to evaluate the clinical and laboratory characteristics of patients with
Kawasaki disease (KD) before and after therapy. Methods Patients with KD were divided …

Risk factors of coronary artery abnormalities and resistance to intravenous immunoglobulin plus corticosteroid therapy in severe Kawasaki disease: an analysis of post …

K Miyata, M Miura, T Kaneko, Y Morikawa… - … Quality and Outcomes, 2021 - ahajournals.org
Background: Coronary artery abnormalities (CAAs) still occur in patients with Kawasaki
disease receiving intensified treatment with corticosteroids. We aimed to determine the risk …

Coronary artery aneurysms are more severe in infants than in older children with Kawasaki disease

SA Cameron, M Carr, E Pahl, N DeMarais… - Archives of disease in …, 2019 - adc.bmj.com
Objective We aimed to compare the severity of coronary artery abnormalities in Kawasaki
disease between infants and older children. Methods We retrospectively reviewed and …

Risk factors of coronary artery aneurysms in Kawasaki disease with a low risk of intravenous immunoglobulin resistance: an analysis of post RAISE

K Iio, Y Morikawa, K Miyata, T Kaneko, M Misawa… - The Journal of …, 2022 - Elsevier
Objective To detect risk factors of coronary artery aneurysm (CAA) development in patients
with Kawasaki disease determined to have a low risk for resistance to primary intravenous …

A 10-year cross-sectional retrospective study on Kawasaki disease in Iranian children: incidence, clinical manifestations, complications, and treatment patterns

P Sadeghi, A Izadi, SY Mojtahedi, L Khedmat… - BMC Infectious …, 2021 - Springer
Background Kawasaki disease (KD) as an acute, systemic vasculitis is the leading cause of
acquired heart disease in children under the age of 5 years. Methods A 10-year cross …

[HTML][HTML] Treatment and coronary artery aneurysm formation in Kawasaki disease: a per-day risk analysis

D Van Stijn, JM Korbee, SA Netea, VC de Winter… - The Journal of …, 2022 - Elsevier
Objective To assess whether 'treatment day'is a significant predicting factor in Kawasaki
disease and imposes a risk for coronary artery aneurysms (CAAs) in a per-day analysis …

Biomarkers for the discrimination of acute Kawasaki disease from infections in childhood

J Zandstra, A Van de Geer, MWT Tanck… - Frontiers in …, 2020 - frontiersin.org
Background: Kawasaki disease (KD) is a vasculitis of early childhood mimicking several
infectious diseases. Differentiation between KD and infectious diseases is essential as KD's …

SIADH in systemic JIA resolving after treatment with an IL-6 inhibitor

JK Hodax, SR Bialo, A Yalcindag - Pediatrics, 2018 - publications.aap.org
Interleukin-6 (IL-6) is implicated in the pathogenesis of both systemic juvenile idiopathic
arthritis (SJIA) and syndrome of inappropriate secretion of antidiuretic hormone (SIADH), but …